The Best Peptides for Fat Loss

When people search for the best peptides for fat loss, they are usually looking at two distinct categories: GLP-1 receptor agonists with substantial clinical backing, and growth-hormone-related peptides used more experimentally in body-composition protocols. Both can play a role, but they carry very different evidence profiles, risk profiles, and regulatory statuses. Understanding those differences is the starting point for any realistic conversation.

Quick-Reference Table

Semaglutide

Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes (Ozempic) and later approved for chronic weight management at a higher dose (Wegovy). It mimics the gut hormone GLP-1, slowing gastric emptying, increasing satiety, and reducing overall caloric intake.

Clinical trials for the weight-management indication reported average body-weight reductions of roughly 15% over 68 weeks in non-diabetic adults with obesity. Those are meaningful numbers by any standard, and they have made semaglutide one of the most discussed fat-loss interventions in recent years.

Common side effects include nausea, vomiting, constipation, and fatigue, particularly when doses are being titrated upward. Rare but serious risks include pancreatitis and, in animal studies, a signal for thyroid C-cell tumors (significance in humans is still being evaluated). Because semaglutide is FDA-approved, it is also the compound with the most established safety monitoring and physician guidance available.

Tirzepatide

Tirzepatide (Mounjaro for diabetes, Zepbound for weight management) is a dual GIP/GLP-1 receptor agonist that activates two incretin pathways simultaneously. Head-to-head data suggests somewhat greater fat loss than semaglutide alone, with trial participants averaging around 20-22% body-weight reduction at the highest doses over 72 weeks.

For individuals who have not achieved their goals on a GLP-1-only approach, tirzepatide represents a step up in efficacy, though the side effect profile is similar and cost remains a significant practical barrier for many. Like semaglutide, this is an FDA-approved medication that should be prescribed and supervised by a physician.

If you are comparing these two in detail, see the semaglutide vs. tirzepatide breakdown.

CJC-1295 and Ipamorelin

CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analogue. Ipamorelin is a growth hormone-releasing peptide (GHRP). They are almost always discussed as a stack because they work through complementary mechanisms: CJC-1295 amplifies the pulse of growth hormone released, while Ipamorelin triggers that pulse with high selectivity and minimal cortisol or prolactin spillover.

Higher growth hormone levels over time can shift body composition, supporting fat oxidation (particularly visceral fat) while helping preserve or build lean muscle. This makes the combination appealing to people prioritizing body recomposition rather than scale weight alone.

Body recomposition from GH-releasing peptides is gradual; results tend to show over 8-16 weeks when diet and training are already consistent.

The evidence here is considerably less robust than for the GLP-1 class. Most data comes from small trials, short durations, or extrapolation from studies on full growth hormone. Neither peptide is FDA-approved for fat loss. Potential side effects include water retention, tingling at injection sites, increased hunger (especially with higher GHRP doses), and over longer use, potential suppression of endogenous hormone axes.

Tesamorelin

Tesamorelin is a stabilized GHRH analogue that carries the distinction of being FDA-approved, specifically for reducing excess visceral abdominal fat in HIV-positive adults with lipodystrophy. Outside that indication, it is investigational.

Studies in the approved indication showed meaningful reductions in visceral adipose tissue measured by imaging, without the same lean-mass loss sometimes seen with other approaches. Because it stimulates natural GH pulsatility rather than providing exogenous HGH, some researchers consider it a cleaner profile. It is, however, expensive, and its prescribable use in otherwise healthy individuals is off-label.

AOD-9604

AOD-9604 is a synthetic fragment of the C-terminus of human growth hormone, designed specifically to activate fat cell receptors involved in lipolysis while avoiding the IGF-1-raising effects of full HGH. The hypothesis is that you get the fat-burning signal without the growth-promoting side effects.

Animal models showed some promise. Human evidence is limited: a handful of short trials with modest or inconsistent results. AOD-9604 failed to gain FDA approval after clinical development in the mid-2000s. It continues to circulate in research peptide markets, but anyone using it should understand they are working well outside the bounds of established clinical medicine.

What Realistic Expectations Look Like

Peptides are not a shortcut that bypasses nutrition and training. The GLP-1 agonists produce their results partly because they reduce appetite and food intake substantially, and the fat loss follows from a sustained caloric deficit. The growth-hormone peptides work slowly and their effects are more pronounced when diet and resistance training are already dialed in.

Key variables that influence outcomes:

• Baseline body composition: those with more fat mass to lose typically see larger absolute changes
• Dietary adherence: no compound overcomes a significant caloric surplus
• Protocol quality: dosing consistency, injection technique, and storage all affect how much of a peptide actually reaches its target
• Individual response: metabolic, hormonal, and genetic factors create genuine variation

If you are reconstituting injectable peptides, the reconstitution guide walks through the math for concentration, and the free calculators at /calculators can handle dose conversion so you are drawing the right volume every time.

Track Your Protocol with Redose

Consistency matters more than the specific compound in most long-term fat-loss outcomes. Redose lets you log every dose with one tap, rotate injection sites automatically, track vial inventory, and generate a PDF summary for your prescribing physician, so nothing falls through the cracks whether you are on week two or week twenty. Download Redose and build the habit from day one.

Conclusion

The best peptides for fat loss depend on what you are trying to accomplish. If appetite reduction and significant scale weight loss are the goal, semaglutide and tirzepatide have the strongest evidence and are available through legitimate medical channels. If body recomposition (shifting fat toward lean mass) is the priority, CJC-1295 + Ipamorelin is the most common investigational approach, though the evidence is much thinner and physician oversight is still important. Tesamorelin and AOD-9604 occupy narrower niches. None of these compounds replace the fundamentals, and all carry real risks worth discussing with a clinician before you start.

This article is educational information, not medical advice. Talk to a qualified healthcare provider before starting any protocol.